Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
Age
13–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia
You may not be if
Patients with a co-morbid serious, uncontrolled systemic illness
Patients with a significant risk of committing suicide
Clareo Health | Oral Aripiprazole Open-Label Rollover Study
